Sample2_PDF.pdf

PDF 348 KB Posted

Attached to
R617--Section 508 Remediation Services (VA-24-00063187)
Solicitation number
36C77624R0132
Issued by

About this file

This document appears to be a quick reference guide for initiating therapy for Parkinson's Disease. It was developed by the Parkinson's Disease Research, Education and Clinical Centers (PADRECCs) and provides guidelines for medication selection and dosing. The guide covers various Parkinson's medications, including Sinemet, Requip, Mirapex, and others, along with starting doses, typical daily doses, and common side effects. It also advises clinicians to assess for impulse control disorder behaviors and monitor for these symptoms during dopamine agonist therapy. The guide serves as a general reference and does not replace clinical judgment or existing practice parameters.

View the file

Other files

File Type Posted
Amedment 0004 Questions and Answers.xlsx XLSX spreadsheet
36C77624R0132 0005.docx DOCX document
Error Correction List.xlsx XLSX spreadsheet
Sample1_PPT.pptx PPTX presentation
52.212-2 EVALUATION CRITERIA.docx DOCX document
Sample3_Interactive_PDF.pdf PDF
36C77624R0132 0004_1.docx DOCX document
PWS_508 REMEDIATION SERVICES -Sept2024.docx DOCX document
52.212-1 ADDENDUM to FAR 52.212-1.docx DOCX document
SectionBCLINs.xlsx XLSX spreadsheet
Purpose of Amendment.docx DOCX document
36C77624R0132 0003_1.docx DOCX document
36C77624R0132 0002.docx DOCX document
36C77624R0132 0001_1.docx DOCX document
36C77624R0132_1.docx DOCX document
Show all 15

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Parkinson’s Disease Quick Reference Guide for Initiating Therapy

The movement disorder experts from the 6 PADRECCs developed the following algorithm to be used as a general guideline, and is not intended to interfere with clinical judgment or replace existing practice parameters.

* Assess for history of Impulse Control Disorder—type behaviors (pathological gambling, eating, spending, sexual, etc) and consider using other agents if significant history and/or concerns exist; monitor for ICD symptoms periodically during dopamine agonist therapy

Please contact one of the six Parkinson’s Disease Research, Education and Clinical Centers (PADRECCs) for additional information or to arrange a consult appointment.

PADRECC/Consortium Hotline: 1-800-949-1001 x5769 Houston PADRECC: 713-794-7841 Philadelphia PADRECC: 215-823-5934 or 888-959-2323 Portland / Seattle PADRECC: 503-721-1091 or 206-277-4560 Richmond PADRECC: 804-675-5931 or 800-784-8381 x5931 San Francisco PADRECC: 415-379-5530 West Los Angeles PADRECC: 310-478-3711 x48001 www.parkinsons.va.gov

Employee Education System Updated May 2019 https://www.parkinsons.va.gov/

Medications Used to Treat Parkinson’s Disease

Medication Name®

(generic name) Start Dose Typical Daily

Dose Common SEs

Sinemet (carbidopa/levodopa)

25/100 1/2 tab TID

25/100 1 tab TID

Sinemet CR (carbidopa/levodopa controlled– release)

25/100 1 tab TID

25/100 or 50/200 1-2 tabs TID

Parcopa (carbidopa/ levodopa orally disin-tegrating tablets)

25/100 1/2 tab TID

25/100 1 tab TID

Comtan (entacapone)

1 (200mg) tab per Sinemet dose

1 (200mg) tab per Sinemet dose

1, urinary discoloration, diarrhea

Stalevo (carbidopa/levodopa/ entacapone)

12.5/50/200 mg TID — or — 25/100/200 mg

TID

25/100/200 mg

TID

Requip (ropinirole HCL)

0.25 mg TID 2.0-5.0 mg TID 1, impulse control disorder (ICD), edema, sedation Mirapex

(pramipexole)

0.125 mg TID 0.5-1.5 mg TID

Neupro (Rotigotine)

2 mg TID 2mg/24 hours 4mg/24 hour

1,2, Application site reaction

Azilect (rasagiline)

0.5 mg daily 1 mg daily 1, 2

Eldepryl (selegiline)

5 mg 5 mg BID 1, 2, psychosis, insomnia

Symmetrel (amantadine)

100 mg daily 100 mg TID pedal edema, psychosis, levido reticularis

Artane (trihexyphenidyl HCL)

1 mg BID 1 mg BID– 2 mg TID

Psychosis, cognitive decline, constipation, urinary retention, dry mouth blurre d vision

Cogentin (benztropine mes ylate)

0.5 mg BID 1-2 mg BID

Side Effect Key 1: Nausea, orthostatic hypotension, dyskinesias, hallucinations, sedation 2: Potential drug interactions with SSRIs (selective serotonin reuptake inhibitors) ICD: Impulse Control Disorder (pathological/impulsive behaviors: gambling, spending, eating, sexual)

File details come from the government source that posted it. Updated .